Literature DB >> 31907278

DEAD Box Protein Family Member DDX28 Is a Negative Regulator of Hypoxia-Inducible Factor 2α- and Eukaryotic Initiation Factor 4E2-Directed Hypoxic Translation.

Sonia L Evagelou1, Olivia Bebenek1, Erin J Specker1, James Uniacke2.   

Abstract

Hypoxia is a deficiency in oxygen delivery to tissues and is connected to physiological and pathophysiological processes such as embryonic development and cancer. The master regulators of oxygen homeostasis in mammalian cells are the heterodimeric hypoxia-inducible transcription factors 1 and 2 (HIF-1 and HIF-2, respectively). The oxygen-labile HIF-2α subunit has been implicated not only in transcription but also as a regulator of eukaryotic initiation factor 4E2 (eIF4E2)-directed hypoxic translation. Here, we have identified the DEAD box protein family member DDX28 as an interactor and negative regulator of HIF-2α that suppresses HIF-2α's ability to activate eIF4E2-directed translation. Stable silencing of DDX28 via short hairpin RNA (shRNA) in hypoxic human U87MG glioblastoma cells caused an increase of eIF4E2 binding to the m7GTP cap structure and the translation of eIF4E2 target mRNAs (including the HIF-2α mRNA itself). DDX28 depletion elevated nuclear and cytoplasmic HIF-2α protein, but HIF-2α transcriptional activity did not increase, possibly due to its already high nuclear abundance in hypoxic control cells. Depletion of DDX28 conferred a proliferative advantage to hypoxic, but not normoxic, cells. DDX28 protein levels are reduced in several cancers, including gliomas, relative to levels in normal tissue. Therefore, we uncover a regulatory mechanism for this potential tumor suppressor in the repression of HIF-2α- and eIF4E2-mediated translation activation of oncogenic mRNAs.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  DEAD box protein; eIF4E2; gene regulation; hypoxia; oxygen; translation

Mesh:

Substances:

Year:  2020        PMID: 31907278      PMCID: PMC7048264          DOI: 10.1128/MCB.00610-19

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

Review 1.  Development of structures and transport functions in the mouse placenta.

Authors:  Erica D Watson; James C Cross
Journal:  Physiology (Bethesda)       Date:  2005-06

2.  A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.

Authors:  Eli M Wallace; James P Rizzi; Guangzhou Han; Paul M Wehn; Zhaodan Cao; Xinlin Du; Tzuling Cheng; Robert M Czerwinski; Darryl D Dixon; Barry S Goggin; Jonas A Grina; Megan M Halfmann; Melissa A Maddie; Sarah R Olive; Stephen T Schlachter; Huiling Tan; Bin Wang; Keshi Wang; Shanhai Xie; Rui Xu; Hanbiao Yang; John A Josey
Journal:  Cancer Res       Date:  2016-09-06       Impact factor: 12.701

Review 3.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

4.  Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype.

Authors:  Annika Jögi; Ingrid Øra; Helén Nilsson; Asa Lindeheim; Yuichi Makino; Lorenz Poellinger; Håkan Axelson; Sven Påhlman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

5.  Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection.

Authors:  Olga Aprelikova; Matthew Wood; Sean Tackett; Gadisetti V R Chandramouli; J Carl Barrett
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  HIF1alpha regulation of Sox9 is necessary to maintain differentiation of hypoxic prechondrogenic cells during early skeletogenesis.

Authors:  Roy Amarilio; Sergey V Viukov; Amnon Sharir; Idit Eshkar-Oren; Randall S Johnson; Elazar Zelzer
Journal:  Development       Date:  2007-10-03       Impact factor: 6.868

7.  Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.

Authors:  Tingfang Yi; Evangelos Papadopoulos; Patrick R Hagner; Gerhard Wagner
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

8.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

Authors:  James Brugarolas; Kui Lei; Rebecca L Hurley; Brendan D Manning; Jan H Reiling; Ernst Hafen; Lee A Witters; Leif W Ellisen; William G Kaelin
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

9.  A unifying model for mTORC1-mediated regulation of mRNA translation.

Authors:  Carson C Thoreen; Lynne Chantranupong; Heather R Keys; Tim Wang; Nathanael S Gray; David M Sabatini
Journal:  Nature       Date:  2012-05-02       Impact factor: 49.962

Review 10.  From structure to function: mitochondrial morphology, motion and shaping in vascular smooth muscle.

Authors:  John G McCarron; Calum Wilson; Mairi E Sandison; Marnie L Olson; John M Girkin; Christopher Saunter; Susan Chalmers
Journal:  J Vasc Res       Date:  2013-07-24       Impact factor: 1.934

View more
  3 in total

1.  Jekyll and Hyde: Activating the Hypoxic Translational Machinery.

Authors:  J J David Ho; Jonathan H Schatz; Jim Uniacke; Stephen Lee
Journal:  Trends Biochem Sci       Date:  2020-12-09       Impact factor: 13.807

Review 2.  Glioma stem cells and their roles within the hypoxic tumor microenvironment.

Authors:  Nathaniel H Boyd; Anh Nhat Tran; Joshua D Bernstock; Tina Etminan; Amber B Jones; G Yancey Gillespie; Gregory K Friedman; Anita B Hjelmeland
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

3.  The pattern of expression and prognostic value of key regulators for m7G RNA methylation in hepatocellular carcinoma.

Authors:  Jianxing Chen; Shibin Yao; Zhijuan Sun; Yanjun Wang; Jili Yue; Yongkang Cui; Chengping Yu; Haozhi Xu; Linqiang Li
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.